Read More

LianBio Announces Topline Results From Phase 3 LIBRA Trial Of TP-03 In Chinese Patients With Demodex Blepharitis; The Co-primary Endpoints Of The LIBRA Trial Were Mite Eradication And Complete Collarette Cure At Day 43

LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced topline results from the Phase 3 LIBRA clinical trial

LIAN